Takakita Co., Ltd. Reports Decline in Sales but Maintains Profitability

TipRanksFeb 3 15:04

Takakita Co 9-Mos Parent Net Y538.00M Vs Net Y515.00M

Dow JonesJan 31 14:32

Takakita: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [Japanese GAAP] (unconsolidated)

JPXJan 31 14:30 · Announcements

Seiwa Construction, Kansai Electric Power Company, ZOZO, Shionogi, Daiichi Sankyo (31st)

※The above Calendar is just a plan and may be subject to change due to the company's circumstances.--------------------------------------- January 31 (Friday) <1803> Shimizu Construction 　<1878> Daito Construction <1884> Nihon Doro 　<1939> Shikoku Electric Engineering <1941> Chudenko 　<1942> Kansai Electric Engineering <1944> Kindan 　<1948> Koden Sha <1949> Sumitomo Electric.

Fisco JapanJan 31 05:30

Volume change rate ranking (9 o'clock) - Takase, Koyo Corporation, etc. ranked in.

In the volume change rate ranking, by comparing the average volume over the last five days with the volume on the distribution day, one can understand the trends of selection and the interests of market participants. ■ Top volume change rates [As of December 4, 9:32] (Comparison of the average volume over the last five days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <9087> Takase 200142.92 400% 0% <7946> Koyo Co. 210084.98 357.11%

Fisco JapanDec 4, 2024 09:17

December 4th [Today's Investment Strategy]

[Fisco Selected Stocks] 【Material Stocks】 JCR Pharma <4552> 727 yen (12/3) Human growth hormone preparation is the main product. The company announced that the first dose was administered to the first subject in the phase 1/2 clinical trial targeting mucopolysaccharidosis type 3B (MPS3B) in Japan for the blood-brain barrier penetrating α-N-acetylglucosaminidase preparation (JR-446) it developed. MPS3B is being co-developed and marketed with Medipal Holdings <7459>.

Fisco JapanDec 4, 2024 08:22